Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

View Full Paper
Ask AI
Bookmark
Share

Authors

EBElizabeth BuddeMRMarissa Del RealMHMarie Hu

Discussion

Loading...

Member takes

Overview

Phase 1 trial reveals 100% complete response in relapsed B-cell lymphomas, suggesting promising safety for BAFFR-CAR T cell therapy.

Key Points

  • Evaluate the safety and efficacy of PMB-CT01, a BAFFR-targeted CAR T cell therapy, in relapsed/refractory B-cell lymphomas.
  • Conducting a phase 1 multicenter trial of PMB-CT01 in patients with r/r B-NHL.
  • Patients received either 50×10^6 or 200×10^6 CAR T cells at two dose levels.
  • Evaluation of safety, including DLTs, ORR, CR rate, and MRD negativity post-treatment.
  • Seven patients treated, with a 100% complete response rate observed.
  • No dose-limiting toxicities or severe CRS/ICANS events occurred.
  • Durable responses up to 32 months, with MRD negativity in MCL patients tested.

Cite This Study

Budde et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd41https://doi.org/10.1182/blood-2025-268
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.2024 · 1 citations
  2. 2Novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL).2026
  3. 3Phase 1 assessment of novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)2025
  4. 4CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations
  5. 5Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma2025